Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (575)	6/19/2000 11:29:00 AM
From: Pierre Borczuk	Respond to of 1475

Interesting sentence in BTRN news release on Yahoo today July 27th will have BTRN + NEJM ``Interest in BioTransplant's technology has been sparked recently by announcement of successful pancreatic islet cell transplantation into patients suffering from diabetes. Details will be spelled out in the July 27 Issue of the New England Journal of Medicine. ``In a pre-release of the paper on June 6, it was reported that 10 patients have become insulin-independent (i.e. they don't need insulin!!!) following the transplantation procedure. All of the patients have Type I diabetes, caused when the immune system destroys the insulin producing islet cells of the pancreas. While the islet cell transplantation proved clinically effective in replacing the patient's need for insulin treatment, the patients require on-going treatment with immunosuppressive drugs to prevent rejection of the insulin producing cells. These drugs often have side effects, rendering transplant recipients susceptible to infections and other complications